Peter Ulrichts
Chief Scientific OfficerDr. Peter Ulrichts serves as Chief Scientific Officer at argenx SE since January 1, 2023. He joined the argenx in 2010. In this role, he oversees the development of all clinical and pre-clinical compounds within argenx’s pipeline. He joined the argenx as a research scientist where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. While at argenx, he headed the development of argenx’ FcRn antagonist efgartigimod until the first-in-human study, after which he transitioned to become the lead scientist of the efgartigimod program. He holds a B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and Ph.D. in Immunology, both from the University of Ghent (Belgium).
Positions
- Company Nameargenx SEStock CodeARGXPositionChief Scientific OfficerColleagues
- TVTimothy Van HauwermeirenCo-Founder & Non-Independent Non-Executive Chairman of the Board
- KMKaren MasseyCEO & Executive Director
- KGKarl GubitzChief Financial Officer
- MMMalini MoorthyGeneral Counsel & Corporate Secretary
- AAAnthony A. RosenbergIndependent Vice Chairman
- HDHans de HaardCo-Founder & Member of Board Advisors
- ACAna CespedesIndependent Non-Executive Director
